Unilumin, Megapixel VR and Userful Certify Advanced AV and LED Solutions for the Enterprise
Userful Corporation, the leading Platform-as-a-Service (PaaS) provider in the Enterprise AV-over-IP market, and Unilumin a world-class LED solution provider of high-quality LED display and lighting products alongside Megapixel VR have certified the integration of their advanced AV technologies.
This validation enables enterprise customers to modernize AV and LED deployments for control rooms, digital signage, meeting spaces and artistic video walls.
Unilumin’s award-winning, market-proven LED display technology and manufacturing expertise along with its successful deployment history pair strongly with Userful’s software-defined AV-over-IP platform to deliver an unsurpassed, centrally managed, secure, and scalable solution for a multitude of AV business applications.
“We are pleased to certify this solution with Userful to further enhance our DV-LED + Megapixel platforms and to provide customers an integrated choice for the broad range of enterprise applications that employ DV-LED,” said Unilumin President, Chris Danley.
“Through the testing and certification of our technologies, Unilumin, Megapixel, and Userful are advancing enterprise applications and providing assurances to AV and IT departments that our solution will meet and exceed expectations,” said Megapixel CEO Jeremy Hochman.
“As we continue to advance our next-generation AV platform, we are excited to collaborate with technology leaders to create best-in-class solutions. Integrating Unilumin and Megapixel’s state-of-the-art displays and controllers with Userful’s platform will provide a superior and unsurpassed solution for the digitally transformed enterprise,” said John Marshall, CEO, Userful.
A certified solution brief that provides an overview and specifications for this multiproduct solution can be found at userful.com/unilumin. The solution will be presented publicly in Unilumin’s booth at InfoComm 2023 in Orlando, Florida.
About Userful
Userful is the world’s leading platform-as-a-service provider in the Enterprise AV-over-IP market—the fastest-growing segment of the IT industry, forecasted to grow from today’s $3B to $51B by 2027, a 60 percent 5-year CAGR. Userful’s software-defined solution is disrupting the market with a Platform-as-a-Service (PaaS) model that allows customers to choose from a suite of highly-integrated AV applications (SaaS offerings, secure, SSO, integrated UI) to support modern service needs across the enterprise. From corporate signage to control room solutions to streaming platforms and data metrics, Userful's solutions enable modernized business operations for IT leaders and the functional departments they support. Userful helps organizations advance the way they work, learn and govern with secure, scalable, and centrally managed solutions for employee and customer engagement worldwide.
About Unilumin
Unilumin is a leading manufacturer of LED display products. In the field of Virtual Production, Unilumin has provided products and services for various industries such as film, XR, broadcast, and commercial. With an office and showroom in NYC and a 36,000+ sq. ft. Orlando Florida facility featuring a service repair center and "Experience Center" showroom, Unilumin is adhering to the corporate mission of "Together, for a Brighter Future", by providing cutting-edge LED products with an advanced sense of designs and one-stop solutions.
About Megapixel VR
Megapixel VR is an innovative technology partner dedicated to delivering fast-tracked, customized, state-of-the-art LED processing and monitoring to the world’s leading entertainment, film & TV, and architectural applications. Superior product design development, manufacturing expertise, and successful deployment, Megapixel delivers unsurpassed visual performance for any project and looks forward to making the world’s next iconic projects a reality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006123/en/
Contact information
Danielle Alfaro
communications@userful.com
403-923-6723
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom